Ozempic Diarrhea That Won't Go Away: When to Worry and What to Do

How common is diarrhea on Ozempic?

In the Ozempic label's pool of two placebo-controlled trials in type 2 diabetes (521 people exposed to Ozempic, mean 32.9 weeks), diarrhea was reported by 8.5% of people on 0.5 mg and 8.8% on 1 mg, compared with 1.9% on placebo [1]. Any gastrointestinal reaction occurred in 32.7% on 0.5 mg and 36.4% on 1 mg versus 15.3% on placebo, and 3.1% and 3.8% respectively stopped treatment for a GI reason, against 0.4% on placebo [1].

Does it settle?

The label's adverse reactions section says the majority of reports of nausea, vomiting and diarrhea occurred during dose escalation [1]. What the label does quantify is severity: severe gastrointestinal reactions occurred in 0.4% of people on 0.5 mg and 0.8% on 1 mg, against 0% on placebo [1].

In a 40-week trial of 959 people comparing 2 mg with 1 mg, GI reactions occurred in 34% on 2 mg and 30.8% on 1 mg, with no new safety signals [1].

The dose steps the label uses

Ozempic starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg; the label moves to 1 mg only after at least 4 weeks on 0.5 mg, and to 2 mg only after at least 4 weeks on 1 mg [1].

Label warnings that relate to diarrhea that keeps going

Kidney injury from fluid loss. The label carries a warning for acute kidney injury due to volume depletion. Postmarketing reports include kidney injury requiring hemodialysis, and the majority of reported events occurred in people who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea [1]. The label directs monitoring of renal function in people reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1]. No dose adjustment is recommended for existing renal impairment [1].

Pancreatitis. The Ozempic label lists persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting, among the signs and symptoms of acute pancreatitis, and the label says to discontinue Ozempic if pancreatitis is suspected [1]. Postmarketing reports include acute and necrotizing pancreatitis, sometimes fatal [1].

Gallbladder disease. Acute gallbladder disease is a labeled warning, and the label says that if cholelithiasis (gallstones) or cholecystitis is suspected, gallbladder studies are indicated [1].

Another common source: metformin

Diarrhea, nausea, flatulence, indigestion, vomiting and abdominal discomfort are the GI effects described for metformin, and a review of metformin intolerance lists slow titration of the immediate-release form and a switch to extended-release among the strategies used to limit them [2]. For someone taking both drugs, either one could be a source of the same symptom.

What is known about treating the diarrhea itself

The nearest evidence for symptomatic treatment is a 2022 American Gastroenterological Association guideline on irritable bowel syndrome with diarrhea, which conditionally recommends loperamide for that condition on very low certainty evidence [3]. That guideline is about IBS-D, not about diarrhea caused by a GLP-1 receptor agonist, and it does not address whether loperamide works for Ozempic-related diarrhea or can be taken with Ozempic.

Would a different drug be easier on the gut?

In an open-label 40-week trial of 1,879 adults with type 2 diabetes, diarrhea was reported by 12% of those on semaglutide 1 mg and by 13% to 16% across the three tirzepatide doses [4]. Diarrhea was therefore not less frequent on tirzepatide in that trial. The trial compared semaglutide 1 mg, not 2 mg, and the Ozempic trials do not establish whether switching medicines would relieve persistent diarrhea [1].